TRVN Trevena Inc
25,390
$0.4157
$0.0043
(1.02%)
| Watchers | 25,390 |
| 52-Wk Low | $0.3001 |
| 52-Wk High | $1.48 |
| Market Cap | $7.62M |
| Volume | 8,719.00 |
| 52-Wk High | $1.48 |
| 52-Wk Low | $0.3001 |
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.comTicker Report • about 1 month ago
Research analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN - Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a "sell...
Share to Feed
Trevena (NASDAQ:TRVN - Get Free Report)s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial...
Trevena Inc (TRVN) has issued an announcement. Discover the latest insights into our business strategies and performance with the newly updated cor...
Analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN - Get Free Report) in a research report issued on Friday. The firm set a "sell" rating on the biopharmaceutical...
StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN Free Report) in a research report report published on Monday morning. The brokerage issued a sell rating on the...
Analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN Get Free Report) in a note issued to investors on Sunday. The brokerage set a sell rating on the...
Trevena (NASDAQ:TRVN Get Free Report) and JanOne (NASDAQ:JAN Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies...
StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN Free Report) in a report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical companys...